Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by M101on Jan 27, 2022 6:44pm
146 Views
Post# 34369067

stunning arrogance

stunning arrogance"And this led to Gottlieb’s next point — since CMS pretty much said that the impact on cognition in the clinical trial isn’t enough to merit approval, what impact would merit such approval? And since nobody knows where that line is, it leaves the entire field of Alzheimer’s drug development in a state of limbo, in Gottlieb’s view."
https://endpts.com/scott-gottlieb-criticizes-cms-in-feud-over-aduhelm-coverage-calls-out-their-lack-of-expertise/

Tanslation: It's the thought that counts, we thought we owned you, we thought you loved us, 
We just want to make billions at public expense, is that so wrong? 

Everyone knows how this game is going to play out, meanwhile we can tune in for the drama. 
<< Previous
Bullboard Posts
Next >>